FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ABHD2-ACAN

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ABHD2-ACAN
FusionPDB ID: 417
FusionGDB2.0 ID: 417
HgeneTgene
Gene symbol

ABHD2

ACAN

Gene ID

11057

176

Gene nameabhydrolase domain containing 2, acylglycerol lipaseaggrecan
SynonymsHS1-2|LABH2|PHPS1-2AGC1|AGCAN|CSPG1|CSPGCP|MSK16|SEDK|SSOAOD
Cytomap

15q26.1

15q26.1

Type of geneprotein-codingprotein-coding
Descriptionmonoacylglycerol lipase ABHD22-arachidonoylglycerol hydrolaseabhydrolase domain containing 2abhydrolase domain-containing protein 2acetylesterasealpha/beta hydrolase domain containing protein 2lung alpha/beta hydrolase 2progesterone-sensitive lipasaggrecan core proteincartilage-specific proteoglycan core proteinchondroitin sulfate proteoglycan core protein 1large aggregating proteoglycan
Modification date2020031320200313
UniProtAcc

P08910

Main function of 5'-partner protein: FUNCTION: Progesterone-dependent acylglycerol lipase that catalyzes hydrolysis of endocannabinoid arachidonoylglycerol (AG) from cell membrane (PubMed:26989199). Acts as a progesterone receptor: progesterone-binding activates the acylglycerol lipase activity, mediating degradation of 1-arachidonoylglycerol (1AG) and 2-arachidonoylglycerol (2AG) to glycerol and arachidonic acid (AA) (PubMed:26989199). Also displays an ester hydrolase activity against acetyl ester, butanoate ester and hexadecanoate ester (PubMed:27247428). Plays a key role in sperm capacitation in response to progesterone by mediating degradation of 2AG, an inhibitor of the sperm calcium channel CatSper, leading to calcium influx via CatSper and sperm activation (PubMed:26989199). May also play a role in smooth muscle cells migration (By similarity). {ECO:0000250|UniProtKB:Q9QXM0, ECO:0000269|PubMed:26989199, ECO:0000269|PubMed:27247428}.

P16112

Main function of 5'-partner protein: FUNCTION: This proteoglycan is a major component of extracellular matrix of cartilagenous tissues. A major function of this protein is to resist compression in cartilage. It binds avidly to hyaluronic acid via an N-terminal globular region.
Ensembl transtripts involved in fusion geneENST idsENST00000352732, ENST00000355100, 
ENST00000565973, ENST00000562254, 
ENST00000352105, ENST00000558207, 
ENST00000559004, ENST00000561243, 
ENST00000439576, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score10 X 10 X 5=5005 X 5 X 3=75
# samples 115
** MAII scorelog2(11/500*10)=-2.18442457113743
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(5/75*10)=-0.584962500721156
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ABHD2 [Title/Abstract] AND ACAN [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ABHD2 [Title/Abstract] AND ACAN [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ABHD2(89698765)-ACAN(89398083), # samples:3
Anticipated loss of major functional domain due to fusion event.ABHD2-ACAN seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
ABHD2-ACAN seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneABHD2

GO:0032570

response to progesterone

26989199

HgeneABHD2

GO:0043401

steroid hormone mediated signaling pathway

26989199

HgeneABHD2

GO:0046464

acylglycerol catabolic process

26989199

HgeneABHD2

GO:0048240

sperm capacitation

26989199



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr15:89698765/chr15:89398083)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ABHD2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across ACAN (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000352732ABHD2chr1589698765+ENST00000439576ACANchr1589398083+7258105851163841957
ENST00000565973ABHD2chr1589698765+ENST00000439576ACANchr1589398083+7479127973266051957
ENST00000355100ABHD2chr1589698765+ENST00000439576ACANchr1589398083+7211101146463371957

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000352732ENST00000439576ABHD2chr1589698765+ACANchr1589398083+0.0030834830.99691653
ENST00000565973ENST00000439576ABHD2chr1589698765+ACANchr1589398083+0.0035846980.99641526
ENST00000355100ENST00000439576ABHD2chr1589698765+ACANchr1589398083+0.0026780610.9973219

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ABHD2-ACAN

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ABHD2chr1589698765ACANchr15893980831011182PNIELTSPRMFTYGILPTWPPTGAAT
ABHD2chr1589698765ACANchr15893980831011199TWPPTGAATEESTEGPSATEVPSASE
ABHD2chr1589698765ACANchr15893980831011358PSGDEERIEWPSTPTVGELPSGAEIL
ABHD2chr1589698765ACANchr15893980831058182PNIELTSPRMFTYGILPTWPPTGAAT
ABHD2chr1589698765ACANchr15893980831058199TWPPTGAATEESTEGPSATEVPSASE
ABHD2chr1589698765ACANchr15893980831058358PSGDEERIEWPSTPTVGELPSGAEIL
ABHD2chr1589698765ACANchr15893980831279182PNIELTSPRMFTYGILPTWPPTGAAT
ABHD2chr1589698765ACANchr15893980831279199TWPPTGAATEESTEGPSATEVPSASE
ABHD2chr1589698765ACANchr15893980831279358PSGDEERIEWPSTPTVGELPSGAEIL

Top

Potential FusionNeoAntigen Information of ABHD2-ACAN in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ABHD2-ACAN_89698765_89398083.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ABHD2-ACANchr1589698765chr15893980831058HLA-B13:02IEWPSTPTV0.9990.8365716
ABHD2-ACANchr1589698765chr15893980831058HLA-B45:01IEWPSTPTV0.99730.8998716
ABHD2-ACANchr1589698765chr15893980831058HLA-B50:02IEWPSTPTV0.99650.7245716
ABHD2-ACANchr1589698765chr15893980831058HLA-B13:01IEWPSTPTV0.98960.9749716
ABHD2-ACANchr1589698765chr15893980831058HLA-B39:06ERIEWPSTP0.98820.9026514
ABHD2-ACANchr1589698765chr15893980831058HLA-B48:01IEWPSTPTV0.97960.5818716
ABHD2-ACANchr1589698765chr15893980831058HLA-B18:01IEWPSTPTV0.87560.79716
ABHD2-ACANchr1589698765chr15893980831058HLA-B47:01IEWPSTPTV0.79110.5523716
ABHD2-ACANchr1589698765chr15893980831058HLA-B50:01IEWPSTPTV0.6740.8456716
ABHD2-ACANchr1589698765chr15893980831058HLA-B52:01IEWPSTPTV0.60910.9906716
ABHD2-ACANchr1589698765chr15893980831058HLA-B41:01IEWPSTPTV0.56970.9527716
ABHD2-ACANchr1589698765chr15893980831058HLA-B39:13IEWPSTPTV0.37640.9827716
ABHD2-ACANchr1589698765chr15893980831058HLA-B45:01EERIEWPSTP0.98480.8734414
ABHD2-ACANchr1589698765chr15893980831058HLA-B35:03WPSTPTVGEL0.98180.8243919
ABHD2-ACANchr1589698765chr15893980831058HLA-B50:02EERIEWPSTP0.96190.6612414
ABHD2-ACANchr1589698765chr15893980831058HLA-B35:02WPSTPTVGEL0.93810.9606919
ABHD2-ACANchr1589698765chr15893980831058HLA-B35:04WPSTPTVGEL0.93810.9606919
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:13RIEWPSTPTV0.88170.7187616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:21RIEWPSTPTV0.83750.7249616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:27RIEWPSTPTV0.8240.6234616
ABHD2-ACANchr1589698765chr15893980831058HLA-B50:01RIEWPSTPTV0.81980.9301616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:04RIEWPSTPTV0.79310.8084616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:60RIEWPSTPTV0.79260.6215616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:17RIEWPSTPTV0.78980.8471616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:24RIEWPSTPTV0.78890.6183616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:67RIEWPSTPTV0.78890.6183616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:30RIEWPSTPTV0.78890.6183616
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:05RIEWPSTPTV0.7810.5924616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:11RIEWPSTPTV0.77880.6395616
ABHD2-ACANchr1589698765chr15893980831058HLA-B13:02RIEWPSTPTV0.77260.9603616
ABHD2-ACANchr1589698765chr15893980831058HLA-B81:01WPSTPTVGEL0.7190.5003919
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:29RIEWPSTPTV0.70250.6191616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:35RIEWPSTPTV0.69420.6276616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:20RIEWPSTPTV0.68710.6224616
ABHD2-ACANchr1589698765chr15893980831058HLA-B41:01RIEWPSTPTV0.54220.9408616
ABHD2-ACANchr1589698765chr15893980831058HLA-B82:01WPSTPTVGEL0.5130.5659919
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:01RIEWPSTPTV0.43560.7027616
ABHD2-ACANchr1589698765chr15893980831058HLA-B47:01RIEWPSTPTV0.33710.6073616
ABHD2-ACANchr1589698765chr15893980831058HLA-B39:13RIEWPSTPTV0.18380.9642616
ABHD2-ACANchr1589698765chr15893980831058HLA-C01:17STPTVGEL0.98790.92521119
ABHD2-ACANchr1589698765chr15893980831058HLA-C01:30STPTVGEL0.93580.92981119
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:06IEWPSTPTV0.99970.6782716
ABHD2-ACANchr1589698765chr15893980831058HLA-B73:01ERIEWPSTP0.98470.8802514
ABHD2-ACANchr1589698765chr15893980831058HLA-B44:10IEWPSTPTV0.94960.6108716
ABHD2-ACANchr1589698765chr15893980831058HLA-B51:07IEWPSTPTV0.60230.9884716
ABHD2-ACANchr1589698765chr15893980831058HLA-B39:08IEWPSTPTV0.46670.8914716
ABHD2-ACANchr1589698765chr15893980831058HLA-B73:01ERIEWPSTPT0.98130.8444515
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:06RIEWPSTPTV0.94340.8058616
ABHD2-ACANchr1589698765chr15893980831058HLA-B35:12WPSTPTVGEL0.93810.9606919
ABHD2-ACANchr1589698765chr15893980831058HLA-B73:01EERIEWPSTP0.92160.838414
ABHD2-ACANchr1589698765chr15893980831058HLA-B39:10WPSTPTVGEL0.8670.9314919
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:07RIEWPSTPTV0.80290.6762616
ABHD2-ACANchr1589698765chr15893980831058HLA-B42:02WPSTPTVGEL0.80030.5416919
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:01RIEWPSTPTV0.78890.6183616
ABHD2-ACANchr1589698765chr15893980831058HLA-B42:01WPSTPTVGEL0.76240.5335919
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:03RIEWPSTPTV0.54490.5385616
ABHD2-ACANchr1589698765chr15893980831058HLA-B48:03RIEWPSTPTV0.37690.7438616
ABHD2-ACANchr1589698765chr15893980831058HLA-B73:01ERIEWPSTPTV0.99960.9437516
ABHD2-ACANchr1589698765chr15893980831058HLA-B73:01DEERIEWPSTP0.99770.8183314
ABHD2-ACANchr1589698765chr15893980831058HLA-C01:03STPTVGEL0.99650.9161119
ABHD2-ACANchr1589698765chr15893980831058HLA-C01:02STPTVGEL0.99240.9221119
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:04IEWPSTPTV0.99770.8042716
ABHD2-ACANchr1589698765chr15893980831058HLA-B18:04IEWPSTPTV0.91880.7937716
ABHD2-ACANchr1589698765chr15893980831058HLA-B18:05IEWPSTPTV0.87560.79716
ABHD2-ACANchr1589698765chr15893980831058HLA-B18:08IEWPSTPTV0.87150.9332716
ABHD2-ACANchr1589698765chr15893980831058HLA-B18:03IEWPSTPTV0.86920.7806716
ABHD2-ACANchr1589698765chr15893980831058HLA-B18:06IEWPSTPTV0.86570.8322716
ABHD2-ACANchr1589698765chr15893980831058HLA-B59:01IEWPSTPTV0.82910.6749716
ABHD2-ACANchr1589698765chr15893980831058HLA-B50:05IEWPSTPTV0.6740.8456716
ABHD2-ACANchr1589698765chr15893980831058HLA-B50:04IEWPSTPTV0.6740.8456716
ABHD2-ACANchr1589698765chr15893980831058HLA-B18:11IEWPSTPTV0.53740.8209716
ABHD2-ACANchr1589698765chr15893980831058HLA-B41:03IEWPSTPTV0.50030.7033716
ABHD2-ACANchr1589698765chr15893980831058HLA-B39:11IEWPSTPTV0.47050.85716
ABHD2-ACANchr1589698765chr15893980831058HLA-B39:31IEWPSTPTV0.43180.9702716
ABHD2-ACANchr1589698765chr15893980831058HLA-B39:02IEWPSTPTV0.37520.9833716
ABHD2-ACANchr1589698765chr15893980831058HLA-B48:02IEWPSTPTV0.23810.745716
ABHD2-ACANchr1589698765chr15893980831058HLA-B35:13WPSTPTVGEL0.97570.831919
ABHD2-ACANchr1589698765chr15893980831058HLA-B35:09WPSTPTVGEL0.93810.9606919
ABHD2-ACANchr1589698765chr15893980831058HLA-B67:01WPSTPTVGEL0.89310.7977919
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:14RIEWPSTPTV0.84020.7053616
ABHD2-ACANchr1589698765chr15893980831058HLA-A02:06RIEWPSTPTV0.83750.7249616
ABHD2-ACANchr1589698765chr15893980831058HLA-B50:04RIEWPSTPTV0.81980.9301616
ABHD2-ACANchr1589698765chr15893980831058HLA-B50:05RIEWPSTPTV0.81980.9301616
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:04RIEWPSTPTV0.63180.8656616
ABHD2-ACANchr1589698765chr15893980831058HLA-B82:02WPSTPTVGEL0.5130.5659919
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:36RIEWPSTPTV0.46480.6958616
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:49RIEWPSTPTV0.39770.7194616
ABHD2-ACANchr1589698765chr15893980831058HLA-B40:12RIEWPSTPTV0.37690.7438616

Top

Potential FusionNeoAntigen Information of ABHD2-ACAN in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)

Top

Fusion breakpoint peptide structures of ABHD2-ACAN

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
7931RIEWPSTPTVGELPABHD2ACANchr1589698765chr15893980831058

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ABHD2-ACAN

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN7931RIEWPSTPTVGELP-8.55667-8.74867
HLA-B14:023BVN7931RIEWPSTPTVGELP-3.49457-4.25557
HLA-B52:013W397931RIEWPSTPTVGELP-7.26725-7.45925
HLA-B52:013W397931RIEWPSTPTVGELP-4.01461-4.77561
HLA-A24:025HGA7931RIEWPSTPTVGELP-7.65911-8.42011
HLA-A24:025HGA7931RIEWPSTPTVGELP-7.10204-7.29404
HLA-B44:053DX87931RIEWPSTPTVGELP-7.5556-8.3166
HLA-B44:053DX87931RIEWPSTPTVGELP-2.76159-2.95359

Top

Vaccine Design for the FusionNeoAntigens of ABHD2-ACAN

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ABHD2-ACANchr1589698765chr15893980831119STPTVGELCCTATGGGATCCTTCCTACTTGGC
ABHD2-ACANchr1589698765chr1589398083314DEERIEWPSTPAATTGACCTCGCCACGCATGTTCACCTATGGGA
ABHD2-ACANchr1589698765chr1589398083414EERIEWPSTPTGACCTCGCCACGCATGTTCACCTATGGGA
ABHD2-ACANchr1589698765chr1589398083514ERIEWPSTPCCTCGCCACGCATGTTCACCTATGGGA
ABHD2-ACANchr1589698765chr1589398083515ERIEWPSTPTCCTCGCCACGCATGTTCACCTATGGGATCC
ABHD2-ACANchr1589698765chr1589398083516ERIEWPSTPTVCCTCGCCACGCATGTTCACCTATGGGATCCTTC
ABHD2-ACANchr1589698765chr1589398083616RIEWPSTPTVCGCCACGCATGTTCACCTATGGGATCCTTC
ABHD2-ACANchr1589698765chr1589398083716IEWPSTPTVCACGCATGTTCACCTATGGGATCCTTC
ABHD2-ACANchr1589698765chr1589398083919WPSTPTVGELTGTTCACCTATGGGATCCTTCCTACTTGGC

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence

Top

Information of the samples that have these potential fusion neoantigens of ABHD2-ACAN

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAABHD2-ACANchr1589698765ENST00000352732chr1589398083ENST00000439576TCGA-AC-A8OQ-01A

Top

Potential target of CAR-T therapy development for ABHD2-ACAN

check button Predicted 3D structure. We used RoseTTAFold.
8_ABHD2-ACAN_t000_.e2e.pdb


check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneABHD2chr15:89698765chr15:89398083ENST00000352732+51110_30179426.0TransmembraneHelical%3B Signal-anchor for type II membrane protein
HgeneABHD2chr15:89698765chr15:89398083ENST00000355100+71310_30179426.0TransmembraneHelical%3B Signal-anchor for type II membrane protein
HgeneABHD2chr15:89698765chr15:89398083ENST00000565973+91510_30179426.0TransmembraneHelical%3B Signal-anchor for type II membrane protein

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result
ABHD2chr1589698765ENST00000352732ACANchr1589398083ENST00000439576

Top

Related Drugs to ABHD2-ACAN

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ABHD2-ACAN

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource